Literature DB >> 6839538

Immunosuppression in Kenyan visceral leishmaniasis.

M Ho, D K Koech, D W Iha, A D Bryceson.   

Abstract

Cell-mediated immune responses were evaluated in 15 patients with active visceral leishmaniasis from Masinga location in eastern Kenya where the disease is endemic. Age and sex matched controls were selected from a village school in the same area. In vivo studies were carried out by skin testing with leishmanin, tuberculin, streptococcal and candida antigens. Lymphocyte blastogenic transformation to the mitogens phytohaemagglutinin (PHA) and concanavalin A (Con A) and the antigens purified protein derivative (PPD), streptokinase-streptodornase (SKSD) and leishmanial antigen (LA) was studied in vitro. The results showed that immunosuppression in visceral leishmaniasis in Kenya was both specific and non-specific. In the majority of patients there was complete anergy to all antigens in vivo and in vitro. The suppression of responses to mitogens was less marked. Recovery of non-specific responses preceded the development of specific immunity. In a small number of patients (23%) immune unresponsiveness to leishmanial antigens persisted 1 year after parasitological cure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839538      PMCID: PMC1536899     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Treatment of Chinese kala-azar with sodium antimony gluconate.

Authors:  E TUCKMAN
Journal:  J Trop Med Hyg       Date:  1949-10

2.  Phytohaemagglutinin-induced lymphocyte transformation test in Indian kala-azar.

Authors:  A C Ghose; J P Haldar; S C Pal; B P Mishra; K K Mishra
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

3.  Immunological features of kala-azar.

Authors:  H R Rezai; S M Ardehali; G Amirhakimi; A Kharazmi
Journal:  Am J Trop Med Hyg       Date:  1978-11       Impact factor: 2.345

Review 4.  Immunological skin testing and interpretation: a plea for uniformity.

Authors:  S E Bates; J Y Suen; B L Tranum
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

5.  Immunological response in Indian kala-azar.

Authors:  B K Aikat; A G Pathania; S Sehgal; P K Bhattacharya; U Dutta; N Pasricha; S Singh; R S Parmar; S Sahaya; L S Prasad
Journal:  Indian J Med Res       Date:  1979-10       Impact factor: 2.375

6.  Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease.

Authors:  A D Bryceson
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

7.  Cell-mediated immunity during natural measles infection.

Authors:  H C Whittle; J Dossetor; A Oduloju; A D Bryceson; B M Greenwood
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

8.  Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis.

Authors:  B Veress; A Omer; A A Satir; A M El Hassan
Journal:  Immunology       Date:  1977-11       Impact factor: 7.397

9.  Characterization of in vitro proliferative responses of human lymphocytes to leishmanial antigens.

Authors:  D J Wyler; F I Weinbaum; H R Herrod
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

10.  Deficiency in kwashiorkor serum of factors required for optimal lymphocyte transformation in vitro.

Authors:  D W Beatty; E B Dowdle
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

View more
  36 in total

1.  Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production.

Authors:  E Pinelli; V P Rutten; M Bruysters; P F Moore; E J Ruitenberg
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

2.  Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains.

Authors:  O M Ulczak; E Ghadirian; E Skamene; J M Blackwell; P A Kongshavn
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

3.  A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis.

Authors:  Smriti Sharma; Richard E Davis; Shweta Srivastva; Susanne Nylén; Shyam Sundar; Mary E Wilson
Journal:  J Infect Dis       Date:  2016-09-06       Impact factor: 5.226

4.  Novel 17-kilodalton Leishmania antigen revealed by immunochemical studies of a purified glycoprotein fraction recognized by murine T lymphocytes.

Authors:  M M Rodrigues; M T Xavier; L Mendonça-Previato; M A Barcinski
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

5.  Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis.

Authors:  B Galvão-Castro; J A Sá Ferreira; K F Marzochi; M C Marzochi; S G Coutinho; P H Lambert
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

6.  Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis.

Authors:  Manuel Modolell; Beak-San Choi; Robert O Ryan; Maggie Hancock; Richard G Titus; Tamrat Abebe; Asrat Hailu; Ingrid Müller; Matthew E Rogers; Charles R M Bangham; Markus Munder; Pascale Kropf
Journal:  PLoS Negl Trop Dis       Date:  2009-07-14

7.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

8.  Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  J P Haldar; S Ghose; K C Saha; A C Ghose
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

9.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12

10.  Recognition of Leishmania antigens by T lymphocytes from nonexposed individuals.

Authors:  M Kemp; M B Hansen; T G Theander
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.